Publié le March 30, 2023
Abstract: Purpose Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts…
Lire la suite
Publié le December 12, 2022
Randomized controlled trials (RCTs), particularly in phase 3, are the preferred sources of evidence for drug approval and reimbursement decisions….
Lire la suite
Publié le January 4, 2022
Join IDDI experts to get updated on efficacy assessment in early-phase trials and more! THURSDAY, FEBRUARY 3 – 9:00 –…
Lire la suite
Publié le November 10, 2021
Be updated on different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1…
Lire la suite
Publié le November 3, 2021
This webinar was presented by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services at IDDI at the 5th Annual Next…
Lire la suite
Publié le October 5, 2021
Demystifying different types of Bayesian and frequentist designs that may be used for first-in-human or other types of phase I…
Lire la suite
Publié le August 4, 2021
With some of the recently developed drugs showing unprecedented response rates and consistent improvement in overall survival in some indications,…
Lire la suite
Publié le July 6, 2021
WATCH RECORDED WEBINAR Drug development in oncology is undergoing several changes brought about by precision medicine, which makes it appealing…
Lire la suite
Publié le June 28, 2021
Nowadays, drug development in oncology is largely centered on the basic premise of precision medicine, according to which targeted agents…
Lire la suite
Publié le June 27, 2021
Estimands Framework: Ensuring alignment between the key scientific question of interest, analysis and interpretation during clinical trial design. The estimands…
Lire la suite